ArticleBiochemistry and biophysics reports2025
Implications of lipoprotein (a) [Lp(a)] gene polymorphic sequence variations and its protein expression in venous thromboembolism (VTE).
Article in Biochemistry and biophysics reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Venous thromboembolism (VTE) is a significant global health concern, with an annual incidence of approximately 1-2 per 1000 individuals. VTE is a major cause of morbidity and mortality worldwide, leading to substantial healthcare costs due to hospitalizations, long-term anticoagulation therapy, recurrent thrombotic events and the need for lifelong clinical management. The burden of VTE is particularly pronounced in aging populations, with incidence rates increasing exponentially after the age of 50. Despite its significant impact, the genetic underpinnings of VTE remain incompletely understood. This study investigates the association of Lp(a) gene polymorphisms (93C > T and 121G > A) and Lp(a) expression with VTE risk. Methods: A case-control study was conducted, enrolling 101 VTE cases and 110 healthy, age- and gender-matched controls. Genotyping was performed using PCR-RFLP, and serum Lp(a) levels were quantified using ELISA. Genotype distribution and their association with VTE risk was determined by statistical analyses. Results: The +121 G > A polymorphism exhibited a significant protective effect, with the GA genotype more prevalent in controls than cases (OR = 0.41, 95 % CI = 0.23-0.73, p = 0.002). Additionally, the combined GA + AA genotypes were significantly associated with a lower VTE risk (OR = 0.44, p = 0.003). Serum Lp(a) levels were elevated in VTE cases (mean VTE 36.41 mg/dl) compared to controls (mean 32.00 mg/dl, p < 0.84). Notably, this difference was most pronounced in the 30-70 mg/dl subgroup (p < 0.01). D-Dimer was significantly elevated in VTE (p < 0.001) and GA + AA genotype was significantly more frequent in control subjects with D-Dimer levels <500 ng/ml (OR = 0.23, 95 % CI = 0.05-0.95, p = 0.04. LP (a)+121 G > A variant genotype was significantly higher in controls for males, smokers and BMI ≤25 than VTE cases (p < 0.05). No significant difference was found in LP(a) +93C > T with VTE risk. Conclusion: Our study concludes the inverse role of Lp(a) polymorphic variation +121 G > A in the pathogenesis of VTE. +93C > T variant and serum lipoprotein (a) levels did not increase the risk of pathogenesis of VTE. However, gender specific impact of LP(a) on VTE is plausible.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.